Dana Mikulenková

<i>TP53</i> mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

Monika Beličková, Jitka Veselá, Anna Jonášová et al. · Oncotarget · 2016 · 55 citations · Full text

Mixed-phenotype Acute Leukemia, Genetics, Genetic Epidemiology +16

Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts

Jaroslav Čermák, Petra Kačírková, Dana Mikulenková et al. · Leukemia Research · 2009 · 39 citations

Hematological Malignancy, Early Myelodysplastic Syndrome, Bone Marrow Failure +7

High level of full‐length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

Anna Jonášová, Radka Bokorová, Jaroslav Poläk et al. · European Journal Of Haematology · 2014 · 30 citations · Full text

Full‐length Cereblon Mrna, Mixed-phenotype Acute Leukemia, Immunology +17

PU.1 Activation Relieves GATA-1–Mediated Repression of <i>Cebpa</i> and <i>Cbfb</i> during Leukemia Differentiation

Pavel Burda, Nikola Čuřík, Juraj Kokavec et al. · Molecular Cancer Research · 2009 · 27 citations

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS

Monika Kaisrlikova, Jitka Veselá, Dávid Kundrát et al. · Leukemia · 2022 · 25 citations · Full text